JGC
NKTR icon

J. Goldman & Co’s Nektar Therapeutics NKTR Stock Holding History

J. Goldman & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,000
Closed -$1.59M – 419
2018
Q1 		$1.59M Buy
+1,000
New +$1.29M 0.07% 231
2017
Q4 		– Sell
-12,000
Closed -$4.32M – 408
2017
Q3 		$4.32M Buy
+12,000
New +$3.75M 0.22% 123

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

J. Goldman & Co's NKTR Position: Q1 2026 in Review

J. Goldman & Co sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 18,352 shares — an estimated $776K sold.

J. Goldman & Co first reported a position in NKTR in Q2 2013 and held it in 9 quarters. The position peaked at $8.55M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • J. Goldman & Co reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 18,352 Nektar Therapeutics shares in Q1 2026, an estimated $776K.
  • J. Goldman & Co first reported a position in Nektar Therapeutics in Q2 2013 and held it in 9 quarters.
  • J. Goldman & Co's Nektar Therapeutics position peaked at $8.55M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.